Announced Wed, 8 Apr · 17:07 IST

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹25.68
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4-2.6+0.5+5.1+5.1+5.5-0.7+2.2+3.3-4.5
Up moveDown movePending
AI summary

Emmessar Biotech & Nutrition Ltd has submitted an initial disclosure to BSE confirming it does not qualify as a 'Large Corporate' under the SEBI circular dated October 19, 2023, which applies to companies with significant borrowing obligations. The company reported NIL outstanding borrowing as on March 31, 2025. It also stated that credit rating is Not Applicable and no fine for borrowing shortfall is applicable. The filing is signed by Priyanka Sharma, Company Secretary and Compliance Officer, dated April 8, 2026. This is a routine compliance submission with no financial impact on the company or shareholders.

Likely market impact

This is a routine compliance filing with no material impact on shareholders or stock price. The company is simply confirming it falls below the borrowing threshold (Rs. 1,000 crore) that would classify it as a 'Large Corporate' under SEBI norms.